The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
ApexOnco Front Page
Recent articles
BeOne's degrader BG-60366 appears to have been discontinued.
The disclosure comes as another of Arcus's TIGIT trials flops.
The company’s conjugate QLS5132 has produced intriguing, but early results.
First-in-human results prompt a biomarker-defined approach for CID-078.
Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
